Back
Speaker illustration

undefined undefined undefined

Presentations Articles

Proprotein convertase subtilisin/kexin 9 (PCSK9) and lipopolysaccharide (LPS) in patients with atrial fibrillation. A biomarker post-hoc analysis from the ATHERO-AF cohort.

Event: ESC Congress 2019

Topic: Inflammation and Immunity

Session: Coronary artery disease inflammation

Access
Like
Thumbnail

digoxin and platelet activation in atrial fibrillation patients.

Event: EHRA 2018

Topic: Mechanisms for Heart Failure and Cardiac Complications in Atrial Fibrillation

Session: Basic Science

Access
Like
Thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation

Event: ESC Congress 2017

Topic: Thrombosis and coagulation

Session: Coronary artery disease: from bench to bedside

Access
Like
Thumbnail

Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation III

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources